Loading
A phase 2 trial of Izalontamab brengitecan in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors is a phase 2 interventional study registered as NCT06006169 by Sichuan Baili Pharmaceutical Co., Ltd., with 186 participants planned, started 2023-10-20 and due to reach its primary completion in 2026-12. Interventions recorded: BL-B01D1, SI-B003. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bispecific ADC, Izalontamab brengitecan, Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin.
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares Bispecific ADC, Izalontamab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/